+1 (207) 809‑0335 FDA, aiming to lower drug costs, moves to speed approval of biosimilars
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them...
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them...
The American Hospital Association warned future tariffs arising from the Trump administration’s Section 232 investigation could disrupt access to an...
The American Hospital Association warned future tariffs arising from the Trump administration’s Section 232 investigation could disrupt access to an...
However, a prolonged lapse in funding could affect other activities underpinning implementation of the law that holds consumers blameless for...
Congress failed to extend the pandemic-era telehealth policies before they lapsed on Oct. 1. Now, providers are scrambling to manage the disruption to...
More than 50 medical groups have signed on to letters calling for healthcare workers to be exempt from new H-1B...
Industry leaders should engage with state lawmakers on AI bills, given many legislators have limited experience with the technology or...
Public companies, which accounted for about half of AI-enabled devices on the market, had a higher rate of recalls and...
The regulation should enable workflow automation to limit paperwork burdens on providers, regulators said. Article By: Emily Olsen Blog Source...
The average monthly bid submitted by insurers for 2026 prescription drug plans increased 33% from last year, according to data...
Phone: +1 307-529-1900
+1 207-809‑0335
E-mail: care@sixaparthealthcare.com
info@sixaparthealthcare.com
© Copyright 2025. www.sixaparthealthcare.com. All Rights Reserved.